Table 3 Treatment and covariate effects on unfavourable outcome for women (N = 426)
From: Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study
| Â | r/n | OR (unadjusted), 95% CI | p | aOR (adjusted), 95% CI | p |
|---|---|---|---|---|---|
Treatment | |||||
 HRZE | 10/138 |  |  |  |  |
 2MHRZ/2MHR | 11/149 | 0.98 (0.40–2.43) | 0.973 | – | – |
 2EMRZ/2MR | 18/139 | 1.93 (0.84–4.39) | 0.119 |  |  |
Age | |||||
 ≤ 30 years | 20/223 | 1.0 |  | – | – |
 > 30 years | 19/203 | 0.95 (0.48–1.88) | 0.881 |  |  |
BMI | |||||
 < 18.5 | 19/189 | 1.0 |  | – | – |
 ≥ 18.5 | 20/237 | 1.03 (0.51–2.12) | 0.926 |  |  |
Race | |||||
 Asian | 15/135 | 1.0 |  |  |  |
 Black | 9/163 | 0.39 (0.14–1.08) | 0.070 | – | – |
 Mixed race and Caucasian | 15/128 | 0.45 (0.14–1.45) | 0.182 |  |  |
Smoking | |||||
 Never smoked | 21/292 | 1.0 |  | 1.0 |  |
 Ever smoked | 18/134 | 2.69 (0.92–7.90) | 0.071 | 2.00 (1.03–3.90) | 0.041 |
HIV | |||||
 Negative | 36/385 | 1.0 |  | – | – |
 Positive | 3/41 | 1.16 (0.28–4.84) | 0.835 |  |  |
Cavities | |||||
 No cavities | 9/110 | 1.0 |  | – | – |
 Cavities | 30/316 | 1.16 (0.51–2.63) | 0.715 |  |  |